Free tool
FAERS Monitor: Savella
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022256 or its brand name (Savella, Milnacipran Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,009
Serious
2,554
43% of reports
Hospitalization
941
Death reported
156
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea699
- pain522
- headache489
- drug ineffective480
- vomiting363
- fatigue347
- dizziness343
- insomnia329
- depression301
- hyperhidrosis288
- off label use276
- anxiety268
- drug hypersensitivity259
- rash219
- arthralgia217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 493 |
| 2010 | 789 |
| 2011 | 586 |
| 2012 | 389 |
| 2013 | 342 |
| 2014 | 304 |
| 2015 | 414 |
| 2016 | 612 |
| 2017 | 375 |
| 2018 | 347 |
| 2019 | 248 |
| 2020 | 251 |
| 2021 | 160 |
| 2022 | 176 |
| 2023 | 139 |
| 2024 | 141 |
| 2025 | 132 |
| 2026 | 87 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperhidrosisSignal | 288 | 7.8 | 7.0 | 1,719 |
| drug hypersensitivitySignal | 259 | 4.7 | 4.2 | 754 |
| depressionSignal | 301 | 4.6 | 4.2 | 863 |
| insomniaSignal | 329 | 4.3 | 3.9 | 848 |
| anxietySignal | 268 | 3.3 | 2.9 | 432 |
| nauseaSignal | 699 | 3.1 | 2.9 | 1,026 |
| painSignal | 522 | 3.0 | 2.7 | 703 |
| headacheSignal | 489 | 2.7 | 2.5 | 551 |
| vomitingSignal | 363 | 2.7 | 2.4 | 397 |
| dizzinessSignal | 343 | 2.4 | 2.2 | 288 |
| arthralgia | 217 | 1.8 | 1.6 | 82 |
| rash | 219 | 1.8 | 1.5 | 72 |
| fatigue | 347 | 1.6 | 1.4 | 72 |
| drug ineffective | 480 | 1.3 | 1.2 | 30 |
| off label use | 276 | 1.1 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.